RxDoctor Payments Data

Samantha McFarland

Family · Spokane Valley, WANPI 1548831217

Payments from drug & device makers

$3,319in general payments, 2019–2025

Across 177 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$584
  • AbbVie$549
  • Exact Sciences$358
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$357
  • Corcept Therapeutics$207
  • Astellas Pharma US Inc$194
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,319100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,319 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$49,040
Medicare patients
202
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide15$32,288
MounjaroTirzepatide19$22,661
JardianceEmpagliflozin12$21,160
Bupropion XlBupropion Hcl36$2,814
Liothyronine Sodium65$2,503
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,101
Levothyroxine Sodium207$1,437
Duloxetine Hcl50$1,348
Armour ThyroidThyroid,pork14$1,174
ProgesteroneProgesterone, Micronized33$1,054
Testosterone Cypionate19$766
Omeprazole44$734
Albuterol Sulfate HfaAlbuterol Sulfate38$720
Lisinopril118$670
Gabapentin49$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$584$32,28815 claims
Lilly USA, LLCMounjaro$93$22,66119 claims
Boehringer IngelheimJardiance$90$21,16012 claims
AbbVieArmour Thyroid, Synthroid$549$1,63127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.

Other family in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →